Cargando…

Expansion of Masood's cytologic index for breast carcinoma and its validity

BACKGROUND: The incidence of breast carcinoma is increasing in developing countries due to adoption of western life-style. Fine-needle aspiration cytology is the initial method to evaluate the palpable breast lesions. The neoadjuvant therapy is helpful in treating high grade rather than low grade br...

Descripción completa

Detalles Bibliográficos
Autores principales: Rekha, TS, Nandini, NM, Dhar, Murali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945622/
https://www.ncbi.nlm.nih.gov/pubmed/24648665
http://dx.doi.org/10.4103/0970-9371.126647
_version_ 1782306554229293056
author Rekha, TS
Nandini, NM
Dhar, Murali
author_facet Rekha, TS
Nandini, NM
Dhar, Murali
author_sort Rekha, TS
collection PubMed
description BACKGROUND: The incidence of breast carcinoma is increasing in developing countries due to adoption of western life-style. Fine-needle aspiration cytology is the initial method to evaluate the palpable breast lesions. The neoadjuvant therapy is helpful in treating high grade rather than low grade breast carcinomas. Masood cytologic index (MCI) delineates all the breast lesions into four groups. The carcinoma group is not graded further. AIM: The present study proposes a method for the expansion of carcinoma group into three grades. MATERIALS AND METHODS: A total of 50 breast carcinoma cases were prospectively studied by comparing expansion of MCI with modified bloom Richardson (MBR) grading over a period of 3 years. RESULTS: Altogether 43/50 cases (86%) had concordance with histopathological grading. The analysis revealed a R2 value of 60%, which was significant. The P value of anisonucleosis, nucleoli and chromatin pattern were 0.001, 0.049 and 0.02 respectively, which were significant. CONCLUSIONS: The present study with the expansion of carcinoma category of MCI into three grades similar to MBR will help the treating surgeon to plan the management accordingly. The results obtained in this study need to be subjected to multicentric study with a large number of cases.
format Online
Article
Text
id pubmed-3945622
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39456222014-03-19 Expansion of Masood's cytologic index for breast carcinoma and its validity Rekha, TS Nandini, NM Dhar, Murali J Cytol Original Article BACKGROUND: The incidence of breast carcinoma is increasing in developing countries due to adoption of western life-style. Fine-needle aspiration cytology is the initial method to evaluate the palpable breast lesions. The neoadjuvant therapy is helpful in treating high grade rather than low grade breast carcinomas. Masood cytologic index (MCI) delineates all the breast lesions into four groups. The carcinoma group is not graded further. AIM: The present study proposes a method for the expansion of carcinoma group into three grades. MATERIALS AND METHODS: A total of 50 breast carcinoma cases were prospectively studied by comparing expansion of MCI with modified bloom Richardson (MBR) grading over a period of 3 years. RESULTS: Altogether 43/50 cases (86%) had concordance with histopathological grading. The analysis revealed a R2 value of 60%, which was significant. The P value of anisonucleosis, nucleoli and chromatin pattern were 0.001, 0.049 and 0.02 respectively, which were significant. CONCLUSIONS: The present study with the expansion of carcinoma category of MCI into three grades similar to MBR will help the treating surgeon to plan the management accordingly. The results obtained in this study need to be subjected to multicentric study with a large number of cases. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3945622/ /pubmed/24648665 http://dx.doi.org/10.4103/0970-9371.126647 Text en Copyright: © Journal of Cytology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Rekha, TS
Nandini, NM
Dhar, Murali
Expansion of Masood's cytologic index for breast carcinoma and its validity
title Expansion of Masood's cytologic index for breast carcinoma and its validity
title_full Expansion of Masood's cytologic index for breast carcinoma and its validity
title_fullStr Expansion of Masood's cytologic index for breast carcinoma and its validity
title_full_unstemmed Expansion of Masood's cytologic index for breast carcinoma and its validity
title_short Expansion of Masood's cytologic index for breast carcinoma and its validity
title_sort expansion of masood's cytologic index for breast carcinoma and its validity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945622/
https://www.ncbi.nlm.nih.gov/pubmed/24648665
http://dx.doi.org/10.4103/0970-9371.126647
work_keys_str_mv AT rekhats expansionofmasoodscytologicindexforbreastcarcinomaanditsvalidity
AT nandininm expansionofmasoodscytologicindexforbreastcarcinomaanditsvalidity
AT dharmurali expansionofmasoodscytologicindexforbreastcarcinomaanditsvalidity